JPY 653.0
(-1.51%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 982.47 Million JPY | 12.78% |
2022 | 871.13 Million JPY | -2.12% |
2021 | 890.03 Million JPY | -12.83% |
2020 | 1.02 Billion JPY | 37.41% |
2019 | 743 Million JPY | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 940 Million JPY | -4.32% |
2023 Q4 | 982.47 Million JPY | 50.71% |
2023 Q3 | 651.92 Million JPY | -7.75% |
2023 Q2 | 706.67 Million JPY | -7.24% |
2023 Q1 | 761.83 Million JPY | -12.55% |
2023 FY | 982.47 Million JPY | 12.78% |
2022 Q3 | 631.23 Million JPY | -15.89% |
2022 Q2 | 750.5 Million JPY | 0.0% |
2022 Q4 | 871.13 Million JPY | 38.01% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Shin Nippon Biomedical Laboratories, Ltd. | 76.3 Billion JPY | 98.712% |
Cosmo Bio Company,Limited | 10.87 Billion JPY | 90.963% |
H.U. Group Holdings, Inc. | 295.35 Billion JPY | 99.667% |
FALCO HOLDINGS Co., Ltd. | 36.42 Billion JPY | 97.303% |
BML, Inc. | 170.99 Billion JPY | 99.425% |
Human Metabolome Technologies, Inc. | 2.6 Billion JPY | 62.262% |
Precision System Science Co., Ltd. | 6.39 Billion JPY | 84.64% |